All In Biotech

Free tool

FAERS Monitor: Yuvezzi

The FDA Adverse Event Reporting System collects reports from patients, clinicians and manufacturers. Counts are unverified reports, not rates: they rise with how widely a drug is used, how long it has been sold and media attention, a report can name several drugs, and a report does not show the drug caused the event.

Last checked: Nov 20, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations

Reports naming NDA 220142 or its brand name (Yuvezzi, Brimonidine Tartrate, Carbachol). Reports on generic versions are filed under their own applications.

Reports

173

Serious

6

3% of reports

Hospitalization

0

Death reported

0

Any cause; not necessarily from the drug

Most reported reactions

MedDRA preferred terms.

  • headache83
  • drug ineffective31
  • vision blurred27
  • eye pain23
  • eye irritation21
  • nausea19
  • visual impairment19
  • dizziness16
  • migraine13
  • ocular hyperaemia9
  • miosis5
  • ocular discomfort5
  • therapeutic response shortened5
  • vitreous detachment5
  • myopia4

Reports by year received

View as table
YearReports
2026173

Disproportionality screen

Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 21,053,986 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.

ReactionReportsPRR95% CI lowerChi-squared
vitreous detachmentSignal5281.2118.41,127
myopiaSignal4204.677.6619
miosisSignal575.831.9298
ocular discomfortSignal554.222.8210
eye painSignal2349.633.91,049
eye irritationSignal2144.429.7849
vision blurredSignal2723.916.9574
ocular hyperaemiaSignal923.112.2169
visual impairmentSignal1918.612.2302
therapeutic response shortenedSignal518.37.766
migraineSignal1316.69.8176
headacheSignal8316.113.81,196
dizzinessSignal163.92.432
nauseaSignal192.91.923
drug ineffectiveSignal312.92.138

A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.